R-6688 Ruxolitinib, Phosphate Salt, >99%

Synonyms : [INCB018424] [INCB18424] [NCB018424] [NCB18424]

Related Terms : [Jakafi]

  • Size
  • US $
  • £
  • ¥
  • 100 mg
  • 145
  • 133
  • 111
  • 23,000
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 218
  • 200
  • 168
  • 34,600
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 247
  • 226
  • 190
  • 39,200
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 425
  • 390
  • 327
  • 67,400
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 732
  • 671
  • 564
  • 116,100
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 1,220
  • 1,119
  • 940
  • 193,500
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 2,540
  • 2,331
  • 1,958
  • 402,900
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 404.36
  • C17H18N6•H3O4P
  • [1092939-17-7]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; soluble in water at 8 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 70 labs worldwide have purchased Ruxolitinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • Ruxolitinib, also known as INCB18424, is a potent and selective Janus kinase JAK1 and JAK2 inhibitor, with IC50s of 2.7 and 4.5 nM, respectively. Verstovsek, S., et al. "INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)." Blood (ASH Annual Meeting Abstracts) 110: 558 (2007).
  • This product is the phosphate salt form of ruxolitinib. We also offer the free base form; please see Ruxolitinib, Free Base, Cat. No. R-6600. The phosphate salt form of ruxolitinib is used for some or all ruxolitinib formulations for use in humans.
  • Ruxolitinib suppressed interleukin-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM). In primary cell cultures, ruxolitinib more selectively inhibited erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67 nM) when compared to healthy donors (IC50 > 400 nM). In a mouse model of JAK2V617F+ myeloproliferative neoplasm, ruxolitinib significantly reduced splenomegaly and circulating levels of inflammatory cytokines, selectively eliminated neoplastic cells, and thus markedly prolonged survival without myelosuppressive or immunosuppressive effects. Quintás-Cardama, A., et al. "Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms." Blood 115: 3109-3117 (2010).
  • Ruxolitinib inhibited phosphorylated signal transducer and activator of transcription 3 (STAT3) in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation. Ruxolitinib reduced the spleen size of the patients with myelofibrosis with or without JAK2 V617F. It also rapidly improved symptoms, including weight loss, fatigue, night sweats, and pruritus. Clinical improvements were associated with significantly reduced levels of circulating inflammatory cytokines. Verstovsek, S., et al. "Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis." N. Engl. J. Med. 363: 1117-1127 (2010).
  • Ruxolitinib inhibited JAK1 and JAK2, with IC50 values of 5.9 nM and 5.7 nM, respectively. It inhibited IL-6 and IL-23 effects at concentrations less than 50 nM. Ruxolitinib was effective in the rat adjuvant arthritis model and multiple murine models of arthritis. Fridman, J.S., et al. "Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050." J. Immunol. 184: 5298-5307 (2010).
  • Ruxolitinib had intriguing results in patients with rheumatoid arthritis and psoriasis by inhibiting inflammatory cytokine signaling, possibly through JAK1 suppression. Mesa, R.A. "Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis." IDrugs 13: 394-403 (2010).
  • This ruxolitinib product is the phosphate salt, whose CAS number is given above. The CAS number of the free base form of ruxolitinib is 941678-49-5.
  • Ruxolitinib phosphate is the active ingredient in the drug sold under the trade name Jakafi® by Incyte Corporation. This drug is currently approved in at least one country for use in patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. NOTE: THE RUXOLITINIB, PHOSPHATE SALT SOLD BY LC LABORATORIES FOR RESEARCH IS NOT JAKAFI® AND IS NOT FOR HUMAN USE. Jakafi® is a registered trademark of Incyte Corporation. LC Laboratories is not affiliated with Incyte Corporation, and the ruxolitinib research compounds sold by LC Laboratories are not manufactured by Incyte Corporation.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.